Navigation Links
Journal of Clinical Investigation Publishes Data Demonstrating Enhanced Antitumor Efficacy of Second Generation DeCIDe™ Technology
Date:3/8/2011

HOUSTON, March 8, 2011 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced the publication of studies comparing AP1903-activated iMyD88/CD40-transduced dendritic cells (DCs) to conventionally matured DCs, in the April 2011 issue of The Journal of Clinical Investigation (JCI).  The studies, conducted by researchers at Baylor College of Medicine, explored the feasibility of a second generation DeCIDe™ vector that combines an inducible toll like receptor (TLR) adapter molecule, iMyD88, with the first generation's inducible CD40 receptor, iCD40.

In the JCI publication, published online on March 7, Narayanan et al reported that chemically induced dimerization (CID) of iMyD88 can replace exogenous, pro-inflammatory adjuvants, providing the danger signal necessary for full DC activation.  Moreover, the manuscript shows for the first time that CD40 and MyD88 signaling domains may be fused into the same iMyD88/CD40 chimeric CID protein, which when activated by AP1903 leads to:  

  • Synergistic activation of downstream signaling molecules in primary DCs.
  • Elaboration of high, therapeutic levels of the T helper 1 (Th1) polarizing cytokine, IL-12, leading to the efficient expansion of CD8+ cytotoxic T lymphocytes (CTLs) in vivo.
  • Full activation of DCs within lymph nodes, the physiologically appropriate site for activation.
  • Elimination of a variety of pre-established tumors in mice, including aggressive B16 melanoma.

"By incorporating TLR signaling into the DeCIDe™ vector, we avoid the need for exogenous TLR adjuvants, while also achieving more potent antitumor activity," stated corresponding author Dr. David Spencer, Vice Chairman of the Department of Pathology and Immunology at Baylor College of Medicine, and Bellicum's Chief Scientific Officer.

Bellicum is working to incorporate this second generation technology into future DeCIDe™ vaccines based on DNA encoding both the iMyD88/CD40 protein and an antigen. In conjunction with a delivery mechanism targeting this DNA to DCs in vivo, such a vaccine could be supplied off the shelf.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is developing clinical applications of chemical induction of dimerization (CID), a drug-based remote control technology that extends the physician's reach beyond the point at which a treatment has been administered. Bellicum's mission is to leverage this smart technology to bring safe, effective, innovative cell therapies to market for patients with serious and life threatening diseases. The company's DeCIDe™ vaccines are designed to kill targeted cells by inducing a potent, durable, fully activated antigen-specific T cell immune response. Lead product BPX-101, an autologous DeCIDe™ vaccine, is in clinical development for patients with metastatic castrate resistant prostate cancer (mCRPC). CaspaCIDe™ is a cell therapy safety switch, permitting the rapid elimination of cells in the event of toxicity. CaspaCIDe™ DLI is a donor lymphocyte infusion administered following a hematopoietic stem cell transplant, in which the safety switch may be activated to resolve graft vs. host disease (GvHD). For more information, visit http://www.bellicum.com.


'/>"/>
SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
2. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
3. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
4. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
5. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
6. Tips from the journals of the American Society for Microbiology
7. Althea Technologies Receives Fast Growth Honors: Deloitte Technology Fast 50 and San Diego Business Journal Fast 100 Awards for the Fifth Consecutive Year
8. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
9. Publication on Tregitopes in Blood Journal of October 2008
10. The Lancets New Online Medical Journal Helps Clinicians and Medical Researchers Find Practice-Changing Evidence Quickly and Easily
11. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , February 12, 2016 ... by Enabling Scientific Understanding of Complex Diseases Such ... Diseases --> --> ... in South Asia and a leading provider of genomics ... $10 million to the GenomeAsia 100K consortium as ...
(Date:2/11/2016)... -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial ... --> --> For the fourth ... million, or $0.34 loss per share, compared to a net loss ... period in 2014. For the year ended December 31, 2015, the ... per share, as compared to a net loss of $60.5 million, ...
(Date:2/11/2016)... HILDEN , Germany and ... QGEN ; Frankfurt Prime Standard: ... new QIAseq Targeted RNA Panels for gene expression profiling, ... next-generation sequencing (NGS). The panels enable researchers to select ... expression fold changes and discover interactions between genes, cellular ...
(Date:2/11/2016)... , Feb. 11, 2016  Spectra BioPharma Selling ... (CSO) that provides biopharma companies the experience, expertise, ... and deploy outsourced sales teams. Created in concert ... addresses both the strategic and tactical needs of ... sales solutions through both personal and non-personal promotion. ...
Breaking Biology Technology:
(Date:2/1/2016)... February 1, 2016 Rising sales ... drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new technological ... size through 2020   ... with new technological advancements to drive global touchfree intuitive ...
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... at John F. Kennedy (JFK) International Airport, New York ... (CBP) identify imposters attempting to enter the United ... belong to them. pilot testing of the system ... at three terminals at JFK during January 2016. --> ...
(Date:1/20/2016)... , Jan. 20, 2016 A market that ... directly benefit from the explosion in genomics knowledge. Learn ... Sound Research. A range of dynamic trends are pushing ... - personalized medicine - pharmacogenomics - pathogen evolution - ... large markets - greater understanding of the role of ...
Breaking Biology News(10 mins):